Tier D — safety concerns noted in the literature
Melanotan II
Non-selective melanocortin agonist.
Evidence & safety
Not approved. Case reports in the literature associate use with changes to melanocytic naevi and concerns around melanoma, plus reported nausea, flushing, and product-quality issues tied to the unregulated supply chain.
We cover this compound as a safety note, not a recommendation. We don't stock or promote it.